New Releases from NCBI BookshelfClascoterone (Winlevi): Indication: For the topical treatment of acne vulgaris in patients 12 years of age and older: Reimbursement Recommendation [Internet].Clascoterone (Winlevi): Indication: For the topical treatment of acne vulgaris in patients 12 years of age and older: Reimbursement Recommendation [Internet].

By admin / March 18, 2025

Canada’s Drug Agency (CDA-AMC) recommends that Winlevi not be reimbursed by public drug plans for the topical treatment of acne vulgaris in patients aged 12 years and older.

New Releases from NCBI BookshelfTools for identification and assessment of harmful gambling: Gambling-related harms: identification, assessment and management: Evidence review B.Tools for identification and assessment of harmful gambling: Gambling-related harms: identification, assessment and management: Evidence review B.

New Releases from NCBI BookshelfMomelotinib (Ojjaara): Indication: For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia: Reimbursement Recommendation [Internet].Momelotinib (Ojjaara): Indication: For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia: Reimbursement Recommendation [Internet].

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top

Leave a Comment Cancel Reply

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.